MX2020008359A - Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. - Google Patents
Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.Info
- Publication number
- MX2020008359A MX2020008359A MX2020008359A MX2020008359A MX2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A MX 2020008359 A MX2020008359 A MX 2020008359A
- Authority
- MX
- Mexico
- Prior art keywords
- amino
- meniere
- adhd
- tourette
- addiction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se proporcionan métodos para tratar el tinnitus, la pérdida de audición neurosensorial aguda, la enfermedad de Meniere, el síndrome de Tourette, el ADHD o la adicción con ácido (1S,3S)-3-amino-4- (difluorometiliden) ciclopentano-1-carboxílico o una sal farmacéuticamente aceptable de este. Se proporcionan métodos para tratar el tinnitus, la pérdida de audición neurosensorial aguda, la enfermedad de Meniere, el síndrome de Tourette, el ADHD o la adicción con ácido (S)-3-amino-4-(difluorom etilenil) ciclopent-1-eno-1-carboxílico. También se proporcionan composiciones terapéuticas que pueden usarse para mejorar uno o más síntomas del tinnitus, la pérdida de audición neurosensorial aguda, la enfermedad de Meniere, el síndrome de Tourette, el ADHD o la adicción.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628020P | 2018-02-08 | 2018-02-08 | |
| US201862628541P | 2018-02-09 | 2018-02-09 | |
| PCT/US2019/017201 WO2019157273A1 (en) | 2018-02-08 | 2019-02-08 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008359A true MX2020008359A (es) | 2020-11-24 |
Family
ID=67475310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008359A MX2020008359A (es) | 2018-02-08 | 2019-02-08 | Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10653652B2 (es) |
| EP (1) | EP3735237A4 (es) |
| JP (1) | JP2021512920A (es) |
| KR (1) | KR20210007948A (es) |
| CN (1) | CN112261938A (es) |
| AU (1) | AU2019216742B2 (es) |
| CA (1) | CA3090258A1 (es) |
| IL (1) | IL276287A (es) |
| MX (1) | MX2020008359A (es) |
| WO (1) | WO2019157273A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3234750A1 (en) | 2015-10-23 | 2017-04-27 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| CN116370448A (zh) | 2017-04-26 | 2023-07-04 | 纳维托制药有限公司 | Sestrin-gator2相互作用的调节剂及其用途 |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| WO2019191525A1 (en) * | 2018-03-29 | 2019-10-03 | Ovid Therapeutics Inc. | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| US11345654B2 (en) | 2018-10-24 | 2022-05-31 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| WO2021087432A1 (en) * | 2019-11-01 | 2021-05-06 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mtorc1 modulator |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| WO2007064586A1 (en) | 2005-11-28 | 2007-06-07 | Orexigen Therapeutics, Inc. | Methods of treating anxiety disorders |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| EP2621475A1 (en) * | 2010-10-02 | 2013-08-07 | Link Research&Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| ES2862673T3 (es) * | 2011-12-12 | 2021-10-07 | Zilentin AG | Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo |
| CA2862816A1 (en) * | 2012-01-27 | 2013-08-01 | Catalyst Pharmaceutical Partners | Method of treating tourette's disorder with gaba-aminotransferase inactivators |
| WO2017062942A2 (en) | 2015-10-09 | 2017-04-13 | Northwestern University | (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, and related compounds as gaba aminotransferase inactivators for the treatment of epilepsy, addiction and hepatocellular carcinoma |
| MX2019009292A (es) | 2017-02-08 | 2019-09-13 | Ovid Therapeutics Inc | Metodos de tratamiento de transtornos convulsivos y sindrome de prader- willi. |
-
2019
- 2019-02-08 WO PCT/US2019/017201 patent/WO2019157273A1/en unknown
- 2019-02-08 EP EP19750667.8A patent/EP3735237A4/en active Pending
- 2019-02-08 JP JP2020542858A patent/JP2021512920A/ja active Pending
- 2019-02-08 US US16/270,856 patent/US10653652B2/en active Active
- 2019-02-08 CN CN201980023215.6A patent/CN112261938A/zh active Pending
- 2019-02-08 AU AU2019216742A patent/AU2019216742B2/en active Active
- 2019-02-08 KR KR1020207025754A patent/KR20210007948A/ko not_active Application Discontinuation
- 2019-02-08 CA CA3090258A patent/CA3090258A1/en active Pending
- 2019-02-08 MX MX2020008359A patent/MX2020008359A/es unknown
-
2020
- 2020-07-26 IL IL276287A patent/IL276287A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3735237A4 (en) | 2021-03-17 |
| US20190240174A1 (en) | 2019-08-08 |
| EP3735237A1 (en) | 2020-11-11 |
| WO2019157273A1 (en) | 2019-08-15 |
| US10653652B2 (en) | 2020-05-19 |
| CA3090258A1 (en) | 2019-08-15 |
| CN112261938A (zh) | 2021-01-22 |
| IL276287A (en) | 2020-09-30 |
| JP2021512920A (ja) | 2021-05-20 |
| KR20210007948A (ko) | 2021-01-20 |
| AU2019216742A1 (en) | 2020-08-13 |
| AU2019216742B2 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008359A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción. | |
| EP4331677A3 (en) | Methods of treating feline coronavirus infections | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| MX2019009190A (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MX2024010140A (es) | Nuevos metodos. | |
| MX2021013913A (es) | Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa. | |
| EP3708168A3 (en) | Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia | |
| CL2018000811A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral. | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| MX2021002322A (es) | Nuevos metodos. | |
| CR20220216A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 | |
| MX2023009631A (es) | Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi. | |
| MX2020011099A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| MX2018012538A (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmaceuticas y metodos para usar los mismos. | |
| GEP20247585B (en) | Furoindazole derivatives | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| MX2020010302A (es) | Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares. | |
| MX2022000143A (es) | Metodos novedosos. | |
| MX2019006768A (es) | Peptidos antimicrobianos. | |
| EA201991688A1 (ru) | Фармацевтические комбинации для лечения рака | |
| MX2020011453A (es) | Combinaciones para tratar el cancer. | |
| MX2021003002A (es) | Composicion para el tratamiento de enfermedades fibroticas, que comprende un compuesto de tioacetamida de benzhidrilo como ingrediente activo. | |
| MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. |